Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease

Digestive Diseases and Sciences

Volumn 61, Issue 3, 2016, Pages 865-871

  Koutroumpakis, Efstratios ^a   Ramos Rivers, Claudia ^a   Regueiro, Miguel ^a   Hashash, Jana G ^a   Barrie, Arthur ^a   Swoger, Jason ^a   Baidoo, Leonard ^a   Schwartz, Marc ^a   Dunn, Michael A ^a   Koutroubakis, Ioannis E ^a   Binion, David G ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cardiovascular risk; Cholesterol; Crohn s disease; Triglycerides; Ulcerative colitis

Indexed keywords

ALBUMIN; BILE ACID SEQUESTRANT; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOMODULATING AGENT; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROID; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; QUALITY OF LIFE; SEX RATIO; STEROID THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS; BLOOD; CASE CONTROL STUDY; COLITIS, ULCERATIVE; DYSLIPIDEMIAS; INFLAMMATORY BOWEL DISEASES; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; REGISTER; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; YOUNG ADULT;

EID: 84958939313     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3932-1     Document Type: Article

References (27)

1. Buchwald H, Rudser KD, Williams SE, et al. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg. 2010;251:1034–1040.
2. Adhyaru BB, Jacobson TA. New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia. Cardiol Clin. 2015;33:181–196.
3. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965;31:321–327.
4. Robertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 2013;9:513–523.
5. Carroll MD, Kit BK, Lacher DA, et al. Trends in lipids and lipoproteins in US adults, 1988–2010. Jama. 2012;308:1545–1554.
6. Borba EF, Carvalho JF, Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol. 2006;13:203–208.
7. Singh S, Kullo IJ, Pardi DS, et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:26–35.
8. Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807–815.
9. Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980–988.
10. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946–955.
11. Becker SA, McClave SA. Lipid profiles in Crohn’s disease patients with and without ileal resection. Am J Gastroenterol. 1996;91:2452.
12. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010;4:478–482.
13. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–288.
14. Koutroubakis IE, Ramos-Rivers C, Regueiro M, et al. Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:1760–1766.
15. Koutroubakis IE, Ramos-Rivers C, Regueiro M, et al. The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory Bowel disease. Inflamm Bowel Dis. 2015;21:1587–1593.
16. Ramos-Rivers C, Regueiro M, Vargas EJ, et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:986–94.e1.
17. Carroll MD, Kit BK, Lacher DA. Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2009–2010. NCHS Data Brief. 2012;1–8.
18. Carroll M, Kit B, Lacher D. Trends in elevated triglyceride in adults: United States, 2001–2012. NCHS Data Brief. 2015;198.
19. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5a–36a.
20. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.
21. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353–356.
22. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921–2928.
23. Miranda-Bautista J, de Gracia-Fernández C, López-Ibáñez M, et al. Lipid profile in inflammatory bowel disease patients on anti-TNFα therapy. Dig Dis Sci. 2015;60:2130–2135.
24. Crockett SD, Hansen RA, Sturmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18:1048–1056.
25. Romanato G, Scarpa M, Ruffolo C, et al. Lipid and phospholipid profile after bowel resection for Crohn’s disease. Int J Colorectal Dis. 2008;23:931–938.
26. Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015;22:119–125.
27. Romanato G, Scarpa M, Angriman I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther. 2009;29:298–307.